Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model

10Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Tissue-type plasminogen activator (tPA) plays a major role in the fibrinolytic system. According to several reports, tPA may also have antiangiogenic properties, especially in combination with a free sulfhydryl donor (FSD). In the rat C6 glioma model, in vitro and in vivo tPA synthesis by glioma cells is enhanced by differentiation therapy. To address the antiangiogenic potential of tPA in this model, tPA was overexpressed in glioma tumors by ex vivo transduction of C6 cells with a lentiviral vector encoding tPA. The transduced cells were subcutaneously implanted into nude mice. Gene transfer allowed for efficient synthesis of tPA by the C6 tumors. Although the treatment of tPA+ tumor-bearing animals with the FSD captopril generated angiostatin in situ and reduced endothelial vascularization of the tumors, it had no effect on tumor growth. Alternative mechanisms could account for this lack of effect and consequently have important implications for vascular the treatment of glioblastoma. © 2008 Nature Publishing Group All rights reserved.

Cite

CITATION STYLE

APA

Solly, F., Fish, R., Simard, B., Bolle, N., Kruithof, E., Polack, B., & Pernod, G. (2008). Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model. Cancer Gene Therapy, 15(10), 685–692. https://doi.org/10.1038/cgt.2008.36

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free